Market Overview:
The global asparaginase market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of leukemia, rising demand for targeted therapies, and growing focus on personalized medicine. The global asparaginase market is segmented by type into Escherichia Coli, Erwinia Chrysanthemi, and Pegylated. The Escherichia Coli segment is expected to dominate the global asparaginase market during the forecast period owing to its high efficacy and low cost. By application, the acute lymphoblastic leukemia (ALL) segment is expected to account for a major share of the global asparaginase market during the forecast period owing to its high prevalence. Geographically, North America dominates the global asparaginase market followed by Europe and Asia Pacific.
Product Definition:
An enzyme that breaks down the amino acid asparagine into simpler molecules. Asparaginase is used to treat acute lymphoblastic leukemia (ALL), a type of cancer that affects white blood cells.
Escherichia Coli:
Escherichia coli is a gram-positive bacteria of the genus Escherichia. It is commonly known as E. coli and sometimes referred to as Escherichia plantarum, after the bacteriologist Albert Günther (1860-1943) who first classified it in 1910. The species was reclassified in 1971, when it was found that E.
Erwinia Chrysanthemi:
Asparaginase is an enzyme that specifically catalyzes the hydrolysis of asparagine to form aspartic acid and glutamic acid. Aspartic acid is used in various applications such as detergents, pharmaceuticals, and food additives while glutamic acid finds application in biotechnology for genetic engineering. Erwinia chrysanthemi produces both enzymes (as well as other products) when grown under certain conditions which makes it a good source for enzyme production.
Application Insights:
The acute lymphoblastic leukemia segment held the largest share of the global asparaginase market in 2017. This is attributed to increasing incidence of cancer among children and adolescents coupled with a high unmet medical need for effective treatment options. Asparaginase has been studied in clinical trials for the treatment of acute lymphoblastic leukemia, however, it is not used as a first-line therapy due to its limited availability and cost barrier.
Other applications include rheumatoid arthritis, osteoarthritis, gouty arthritis, lupus nephrological syndrome and other diseases related to chronic inflammation such as atherosclerosis or rheumatoid arthritis.
Regional Analysis:
North America accounted for the largest share of over 40.0% in 2017, owing to the presence of a large number of patients suffering from ALL and AML. In addition, increasing R&D activities by major companies is also expected to drive the market growth in this region. For instance, every year until 2016 Novartis Corporation had been funding more than USD X million for research projects on cancer immunotherapy at universities across U.S., which eventually helped it gain significant competitive advantage in cancer immunotherapy market (Novartis Corp 2015).
Asia Pacific asparaginase market is anticipated to grow at a lucrative rate during the forecast period due to rising healthcare expenditure and improving healthcare infrastructure coupled with growing awareness about blood disorders among people especially children & adolescents (Singh et al., 2018).
Growth Factors:
- Increasing incidence of acute lymphoblastic leukemia (ALL)
- Rising demand for better and more effective treatments for ALL
- Growing number of clinical trials for asparaginase therapy
- Increasing awareness about the benefits of asparaginase therapy
- Technological advancements in the manufacturing of asparaginase
Scope Of The Report
Report Attributes
Report Details
Report Title
Asparaginase Market Research Report
By Type
Escherichia Coli, Erwinia Chrysanthemi, Pegylated
By Application
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Other
By Companies
Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, Qianhong Bio-pharma, Taj Pharmaceuticals, Mingxing Pharma, SL Pharma, United Biotech
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Asparaginase Market Report Segments:
The global Asparaginase market is segmented on the basis of:
Types
Escherichia Coli, Erwinia Chrysanthemi, Pegylated
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Jazz Pharmaceuticals
- Shire
- Medac GmbH
- Kyowa Hakko Kirin
- Qianhong Bio-pharma
- Taj Pharmaceuticals
- Mingxing Pharma
- SL Pharma
- United Biotech
Highlights of The Asparaginase Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Escherichia Coli
- Erwinia Chrysanthemi
- Pegylated
- By Application:
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Asparaginase Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Asparaginase is a medication used to treat cancer. It works by breaking down asparagine, which is a building block of proteins. This can help to stop the growth of cancer cells.
Some of the major players in the asparaginase market are Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, Qianhong Bio-pharma, Taj Pharmaceuticals, Mingxing Pharma, SL Pharma, United Biotech.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Asparaginase Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Asparaginase Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Asparaginase Market - Supply Chain
4.5. Global Asparaginase Market Forecast
4.5.1. Asparaginase Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Asparaginase Market Size (000 Units) and Y-o-Y Growth
4.5.3. Asparaginase Market Absolute $ Opportunity
5. Global Asparaginase Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Asparaginase Market Size and Volume Forecast by Type
5.3.1. Escherichia Coli
5.3.2. Erwinia Chrysanthemi
5.3.3. Pegylated
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Asparaginase Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Asparaginase Market Size and Volume Forecast by Application
6.3.1. Acute Lymphoblastic Leukemia
6.3.2. Acute Myeloid Leukemia
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Asparaginase Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Asparaginase Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Asparaginase Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Asparaginase Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Asparaginase Demand Share Forecast, 2019-2029
9. North America Asparaginase Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Asparaginase Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Asparaginase Market Size and Volume Forecast by Application
9.4.1. Acute Lymphoblastic Leukemia
9.4.2. Acute Myeloid Leukemia
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Asparaginase Market Size and Volume Forecast by Type
9.7.1. Escherichia Coli
9.7.2. Erwinia Chrysanthemi
9.7.3. Pegylated
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Asparaginase Demand Share Forecast, 2019-2029
10. Latin America Asparaginase Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Asparaginase Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Asparaginase Market Size and Volume Forecast by Application
10.4.1. Acute Lymphoblastic Leukemia
10.4.2. Acute Myeloid Leukemia
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Asparaginase Market Size and Volume Forecast by Type
10.7.1. Escherichia Coli
10.7.2. Erwinia Chrysanthemi
10.7.3. Pegylated
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Asparaginase Demand Share Forecast, 2019-2029
11. Europe Asparaginase Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Asparaginase Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Asparaginase Market Size and Volume Forecast by Application
11.4.1. Acute Lymphoblastic Leukemia
11.4.2. Acute Myeloid Leukemia
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Asparaginase Market Size and Volume Forecast by Type
11.7.1. Escherichia Coli
11.7.2. Erwinia Chrysanthemi
11.7.3. Pegylated
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Asparaginase Demand Share, 2019-2029
12. Asia Pacific Asparaginase Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Asparaginase Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Asparaginase Market Size and Volume Forecast by Application
12.4.1. Acute Lymphoblastic Leukemia
12.4.2. Acute Myeloid Leukemia
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Asparaginase Market Size and Volume Forecast by Type
12.7.1. Escherichia Coli
12.7.2. Erwinia Chrysanthemi
12.7.3. Pegylated
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Asparaginase Demand Share, 2019-2029
13. Middle East & Africa Asparaginase Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Asparaginase Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Asparaginase Market Size and Volume Forecast by Application
13.4.1. Acute Lymphoblastic Leukemia
13.4.2. Acute Myeloid Leukemia
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Asparaginase Market Size and Volume Forecast by Type
13.7.1. Escherichia Coli
13.7.2. Erwinia Chrysanthemi
13.7.3. Pegylated
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Asparaginase Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Asparaginase Market: Market Share Analysis
14.2. Asparaginase Distributors and Customers
14.3. Asparaginase Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Jazz Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Shire
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Medac GmbH
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Kyowa Hakko Kirin
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Qianhong Bio-pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Taj Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Mingxing Pharma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. SL Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. United Biotech
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook